C-Peptide Testing Evolves to Better Classify Diabetes Types and Predict Treatment Response
New review reveals how C-peptide measurement is advancing diabetes care through improved testing methods and clinical applications.
Summary
C-peptide, a biomarker of pancreatic beta-cell function, is becoming increasingly important for diabetes classification and treatment decisions. This comprehensive review examines current testing methods, from simple random blood tests to stimulated protocols, and their clinical applications. Random non-fasting C-peptide shows excellent performance compared to gold-standard testing for identifying severe insulin deficiency. The review highlights ongoing challenges with assay standardization between manufacturers and explores emerging roles in predicting treatment response and classifying diabetes subtypes beyond traditional type 1 and type 2 categories.
Detailed Summary
C-peptide measurement has emerged as a critical tool in modern diabetes care, offering insights into pancreatic beta-cell function that guide both diagnosis and treatment decisions. This comprehensive review by Briggs and colleagues examines the evolution of C-peptide testing across multiple dimensions - from laboratory methods to clinical applications.
The authors systematically evaluated different testing approaches, including fasting, random, and stimulated C-peptide measurements in blood and urine samples. A key finding is that random non-fasting C-peptide performs remarkably well compared to gold-standard stimulated tests for classifying severe insulin deficiency, making it highly practical for routine clinical use. Using established cut-offs (≤200 pmol/L for type 1 diabetes, >600 pmol/L for type 2), random testing showed high sensitivity and specificity.
The review reveals significant analytical challenges that impact clinical interpretation. Despite international standardization efforts, C-peptide assays from different manufacturers show substantial variation - up to 36.6% difference between some platforms. This variability has important implications for establishing universal clinical cut-offs and comparing research results across studies.
Beyond traditional diabetes classification, C-peptide measurement is finding new applications in predicting treatment response and identifying diabetes subtypes. The biomarker may help clinicians determine which patients will benefit from specific therapies and could play a role in precision medicine approaches to diabetes care.
The clinical implications are substantial for the estimated 537 million adults worldwide with diabetes. More accurate classification could lead to better treatment selection, while the convenience of random testing makes assessment more accessible in various clinical settings. However, the authors emphasize the need for continued standardization efforts and careful consideration of assay-specific cut-offs in clinical practice.
Key Findings
- Random non-fasting C-peptide performs as well as gold-standard stimulated tests for diabetes classification
- C-peptide assays show up to 36.6% variation between manufacturers despite standardization efforts
- Urine C-peptide testing offers non-invasive assessment with good correlation to blood levels
- C-peptide may predict treatment response and help classify diabetes subtypes beyond type 1/type 2
- Point-of-care capillary testing shows promise for expanding access to C-peptide assessment
Methodology
This is a comprehensive narrative review examining preanalytical, analytical, and clinical aspects of C-peptide testing. The authors systematically evaluated different sample types, testing protocols, and analytical methods while reviewing recent literature on clinical applications and standardization efforts.
Study Limitations
The review highlights ongoing challenges with assay standardization that limit comparability between studies and clinical settings. Most published studies don't specify which C-peptide assay was used, making result interpretation and reproducibility difficult across different healthcare systems.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.